Insider buying last 90 days
No open-market insider purchases were filed for DNTH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DNTH insider filing, plotted on the chart in Gekko.Open DNTH in Gekko
NASDAQ: DNTH
Dianthus Therapeutics (DNTH) Stock Analysis & Forecast
Sep 28 close
$87.83−0.72 (−0.8%)
Gekko Brief
AI summaryDianthus Therapeutics sees little in the way of company news this week, with coverage limited to a general profile piece and a filing showing Bank of America Corp DE taking a new position of 256,833 shares valued at approximately $25 million, a 0.47% stake in the company.
DNTH closes at $87.83, down 0.8%, sitting between its 50-day average of $105.94 and 200-day average of $80.23, reflecting a mixed trend picture. The GekkoIndex reads 71.3, placing the stock in the Buying zone, while shares trade 26.7% below the Gekko Fair Value of $119.89. Over the past month the stock is down 21.3%, though it remains up 145.1% over the past year.
The next earnings date falls on 5 November 2026, 37 days out and beyond a typical 20-trading-day hold; the last report on 4 August 2026 showed an EPS of -0.9 against a -0.93 estimate, with a 6.1% reaction, part of a record of 3 beats in 8 quarters. No insider, Congress, or unusual options activity appears in the current windows. Seasonality is a noted headwind, with the next 20 trading days averaging -10% over 5 years and rising in only 1 of them. Analyst coverage stands at 13 firms, all with buy ratings, and a consensus target of $140.80.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Dianthus Therapeutics price vs fair value
Close $87.83200-day averageGekko Fair Value $119.89
Dianthus Therapeutics quick facts
- Market cap
- $4.91B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.12
- Revenue, TTM
- $1.90M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.06
- Volume
- 642,543 avg 839,706
- 1-year return
- +145.1%
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±11.3%
- 50-day average
- $105.94
- 200-day average
- $80.23
- Next earnings
- Nov 5
- Shares outstanding
- 55.93M
Dianthus Therapeutics swing-trade checklist
Dianthus Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $87.83 sits between the 50-day ($105.94) and 200-day ($80.23) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
71.3, Buying
Reading 71.3 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
26.7% below
Price is 26.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−10.0% on average
From this point in the calendar, the next 20 trading days averaged −10% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Dianthus Therapeutics stock chart and price history
Dianthus Therapeutics closed at $87.83 on Sep 28, 2026, +145.1% over the past year, inside a 52-week range of $32.22 to $117.88.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −21.3%
- 3 months
- −8.2%
- 6 months
- +8.3%
- 1 year
- +145.1%
The full DNTH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DNTH in Gekko
Follow Dianthus Therapeutics through every session
Put DNTH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DNTH in GekkoFree for 7 days. No credit card required.
About Dianthus Therapeutics
Dianthus Therapeutics works on medicines for people with serious autoimmune conditions, operating as a clinical-stage biotechnology company. Its furthest-along candidate, claseprubart, is a monoclonal antibody built for a longer half-life, stronger potency, and narrow targeting of only the active form of the C1s complement protein. It is best known for this program among its pipeline of experimental treatments.
The company also has a second candidate, DNTH212, described as a bifunctional fusion protein. This molecule is designed to act on plasmacytoid dendritic cells through BDCA2 to lower Type 1 interferon output, while at the same time blocking BAFF and APRIL to limit B cell activity. As a clinical-stage business, Dianthus Therapeutics centers its work on advancing these drug candidates through development rather than on selling approved products.
Dianthus Therapeutics was established in 2019 and has its headquarters in New York, New York. Its shares are listed on the NASDAQ under the ticker DNTH.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- dianthustx.com
Dianthus Therapeutics GekkoIndex: the smart money zone
Dianthus Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.3, in the Buying zone, down 0.3 points over five sessions.
71.3Buying
Down 0.3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying (current zone) | 12 | +21.4% | +40.4% |
| Accumulation | 179 | +2.6% | +9.7% |
| Neutral | 423 | +0.8% | +4.5% |
| Distribution | 41 | +3.6% | +8.3% |
| Selling | 17 | +9.6% | +22.4% |
Average DNTH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the DNTH price, zone by zone.Track DNTH in Gekko
Is Dianthus Therapeutics stock overvalued? Gekko Fair Value
Dianthus Therapeutics trades 26.7% below Gekko Fair Value of $119.89, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Dianthus Therapeutics shares are worth, recalculated every trading day.
$119.89
Gekko Fair Value, Sep 26, 2026
26.7% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open DNTH in Gekko
Dianthus Therapeutics insider and Congress trading
No open-market insider purchases were filed for Dianthus Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DNTH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DNTH, plotted on the chart in Gekko.Open DNTH in Gekko
Buybacks
Dianthus Therapeutics has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2025
- $317K
- As a share of market cap
- 0.01%
From company filings.
Dianthus Therapeutics earnings: next date and track record
Dianthus Therapeutics reports on Nov 5, 2026 (37 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 5, 2026
37 days away
- EPS estimate
- −$0.94
- Revenue estimate
- $444K
3 of 8reports beat the EPS estimate
±5.8%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.90 est −$0.93 | $761K est $297K | +6.1% |
| May 5, 2026 | −$0.85 est −$1.10 | $463K est $404K | +1.2% |
| Nov 5, 2025 | −$0.97 est −$0.86 | $396K est $398K | +9.7% |
| Aug 7, 2025 | −$0.88 est −$0.86 | $193K est $865K | −8.0% |
| May 12, 2025 | −$0.82 est −$0.71 | $1.16M est $807K | −3.8% |
| Mar 11, 2025 | −$0.81 est −$0.76 | $1.33M est $955K | −10.0% |
| Nov 7, 2024 | −$0.72 est −$0.59 | $2.17M est $844K | −1.2% |
| Aug 8, 2024 | −$0.51 est −$0.55 | $1.86M est $320K | +6.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Dianthus Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Dianthus Therapeutics is $140.80, +60.3% from the last close, from 13 firms rating the stock in the last 90 days.
$140.80consensus 12-month target, +60.3% from the last close
Now $87.83Avg $140.80
Low $122High $200
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | J.P. Morgan | — | — |
| Sep 18 | William Blair | — | — |
| Sep 11 | J.P. Morgan | $135 | +53.7% |
| Sep 4 | Citi | $156 | +77.6% |
| Aug 13 | Stifel Nicolaus | $133 | +51.4% |
+40.4%average 20-day move after past Buying readings
−10.0%average move over the next 20 trading days in the last 5 years
±5.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Dianthus Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Dianthus Therapeutics averaged −10.0% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.6% | 1 of 5 |
| Next 10 trading days | −8.3% | 1 of 5 |
| Next 15 trading days | −7.2% | 1 of 5 |
| Next 20 trading days | −10.0% | 1 of 5 |
| Next 30 trading days | −8.1% | 2 of 5 |
For scale, DNTH’s typical 20-trading-day move in either direction is about 11.3%.
Dianthus Therapeutics market cap and key statistics
Dianthus Therapeutics’s market cap is $4.91B and revenue of $1.90M over the last twelve months.
Valuation
- Market cap
- $4.91B
- EPS, TTM
- −$4.12
- Gekko Fair Value
- $119.89
Trading
- Volume
- 642,543
- Avg volume, 20 days
- 839,706
- 52-week high
- $117.88
- 52-week low
- $32.22
- Shares outstanding
- 55.93M
Financials
- Revenue, TTM
- $1.90M
- Profit margin
- 0%
- Return on equity
- -26.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.06
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±11.3%
Dianthus Therapeutics stock news this week
2 headlines about Dianthus Therapeutics from the past week, newest first, each linking to the publisher.
- Dianthus Therapeutics, Inc. (DNTH) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 26
- Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTHMarketBeat, Sep 24
Dianthus Therapeutics peers
Dianthus Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Dianthus Therapeutics stock FAQ
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $4.91B at the Sep 28, 2026 close of $87.83, with 55.93M shares outstanding.
What is the Dianthus Therapeutics stock forecast?
The consensus analyst 12-month price target for Dianthus Therapeutics is $140.80, +60.3% from the last close. Of the 13 firms that rated the stock in the last 90 days, 13 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Dianthus Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Dianthus Therapeutics is undervalued: the Sep 28, 2026 close of $87.83 is 26.7% below Gekko Fair Value of $119.89. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Dianthus Therapeutics report earnings next?
Dianthus Therapeutics is expected to report on Nov 5, 2026 (37 days away). Analysts expect earnings of −$0.94 per share on revenue of $444K. Dianthus Therapeutics beat the earnings estimate in 3 of its last 8 reports, moving 5.8% on average across the report.
What is Dianthus Therapeutics’s 52-week high and low?
Dianthus Therapeutics’s 52-week high is $117.88 and its 52-week low is $32.22; it closed at $87.83 on Sep 28, 2026, +145.1% over the past year. Over the last five years the shares peaked at $135.84 on Nov 5, 2021.
Is Dianthus Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Dianthus Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.